NEW YORK -- IntraLinks® (NYSE: IL), a global technology provider of inter-enterprise content management and collaboration solutions, announced the results of the 2012 IntraLinks Global Investigator Site Survey. The survey looked at what methods are currently used for clinical trial document exchange, and the effectiveness of those methods. The survey results revealed an increased prevalence in the use of online tools from 65 percent in 2011 to 74 percent in 2012, but that there is a significant opportunity for investigator sites to improve efficiency through web-based solutions for clinical trial exchange.
The survey findings show that the majority of investigator sites are using traditional methods – email, courier and fax – as a primary tool for clinical trial document exchange. Adoption of electronic tools has grown, yet these methods continue to fall short in addressing the current document exchange needs atmost clinical trial sites:
77% of respondents (a 4% increase over the 2011 survey) use traditional methods – email (64%), courier (8%), and fax (5%) – as their primary tool for clinical trial document exchange
20% of respondents use web-based document exchange tools including Electronic Data Capture technologies (85%) and clinical portals (83%) as their main way of exchanging clinical trial documents
3% of respondents didn't select a primary method
The survey results indicate that investigator sites are experiencing significant inefficiencies and productivity challenges as a result of the ongoing use of email, courier, and fax:
58% of respondents track due dates for information, current status, or milestones manually
66% of respondents spend at least two hours, and in some cases more than nine hours, per week searching for documents
78% of respondents (up 4% from 2011) report resending documents to sponsors and Contract Research Organizations (CROs) at least once or twice, and in some cases more than five times, a week
The survey found that respondents recognize the benefits of web-based clinical document exchange tools:
71% of respondents cited being able to access updated information right away and reducing the amount of paper they use as advantages
60% of respondents cited being able to keep track of information easily as a benefit
49% of respondents cited not spending as much time searching for information as a benefit
The survey results also showed that most respondents are conducting numerous studies and those that use online clinical tools such as electronic data capture and clinical portals have a significant number of passwords and logins:
89% of respondents have conducted three to 15+ studies over the last 12 months
53% of respondents are running four to 15+ concurrent studies
83% of respondents use online clinical trial portals, up from 71 percent in 2011
"There needs to be a paradigm shift to evaluate clinical document exchange challenges from a clinical community perspective," said George Waidell, VP, life sciences practice at IntraLinks. "It is pivotal for sponsors and CROs to consider investigator sites' needs and the clinical community perspective. Deploying web-based clinical document exchange tools will enable them to reach optimal productivity gains and efficiencies."
The IntraLinks Global Investigator Site Survey was conducted online by CenterWatch, a trusted source of clinical trials information for both professionals and patients. There were 600 responses to the survey with 71% of respondents based in North America, 19% in Europe, and 5% in Asia Pacific. For more information on the survey, contact your IntraLinks representative.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.